Amwill Health Care Ltd
Incorporated in 2009, Amwill Health Care is in the wholesale trading of pharmaceutical products[1]
- Market Cap ₹ 82.0 Cr.
- Current Price ₹ 41.0
- High / Low ₹ 83.5 / 28.9
- Stock P/E 7.18
- Book Value ₹ 40.3
- Dividend Yield 0.00 %
- ROCE 20.5 %
- ROE 15.2 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.02 times its book value
- Company has delivered good profit growth of 68.1% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.8%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 168 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 17 | 26 | 28 | 42 | 37 | 45 | |
| 18 | 22 | 24 | 25 | 26 | 32 | |
| Operating Profit | -1 | 4 | 4 | 17 | 12 | 13 |
| OPM % | -6% | 14% | 15% | 40% | 31% | 29% |
| 0 | -0 | 0 | 0 | 1 | 3 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 |
| Profit before tax | -1 | 3 | 4 | 17 | 12 | 15 |
| Tax % | -3% | 23% | 25% | 25% | 10% | 26% |
| -1 | 3 | 3 | 12 | 11 | 11 | |
| EPS in Rs | -333.33 | 856.67 | 1,036.67 | 2,500.00 | 5.36 | 5.71 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 17% |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 68% |
| 3 Years: | 54% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -45% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | 27% |
| Last Year: | 15% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.03 | 0.03 | 0.03 | 0.05 | 20 | 20 |
| Reserves | -1 | 1 | 5 | 17 | 49 | 61 |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| 9 | 5 | 8 | 2 | 2 | 6 | |
| Total Liabilities | 8 | 7 | 12 | 19 | 71 | 87 |
| 1 | 0 | 1 | 1 | 1 | 1 | |
| CWIP | 0 | 0 | 0 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 3 |
| 7 | 6 | 12 | 18 | 70 | 83 | |
| Total Assets | 8 | 7 | 12 | 19 | 71 | 87 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 0 | 3 | 5 | -3 | 6 | 8 | |
| -1 | -0 | -1 | -1 | -46 | 6 | |
| 0 | 0 | -0 | -0 | 41 | -0 | |
| Net Cash Flow | -1 | 3 | 3 | -4 | 1 | 14 |
| Free Cash Flow | -1 | 3 | 4 | -4 | 5 | 7 |
| CFO/OP | -26% | 108% | 135% | 6% | 62% | 88% |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 93 | 12 | 16 | 114 | 163 | 168 |
| Inventory Days | 66 | 22 | ||||
| Days Payable | 39 | 66 | ||||
| Cash Conversion Cycle | 93 | 12 | 16 | 141 | 163 | 124 |
| Working Capital Days | -45 | -25 | -38 | 111 | 166 | 150 |
| ROCE % | 1,069% | 133% | 153% | 28% | 21% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Hair Care SKUs Number |
|
|
| Lip Care SKUs Number |
||
| Personal Care and Hygiene SKUs Number |
||
| Sales and Marketing Team Size Number |
||
| Skin Care SKUs Number |
||
| Total Employee Count Number |
||
| Total SKU Count Number |
||
| Geographic Presence (States) Number |
||
Extracted by Screener AI
Documents
Announcements
-
SUBMISSION OF STATEMENT OF DEVIATION OR VARIATION IN UTILIZATION OF FUNDS RAISED THROUGH INITIAL PUBLIC OFFER (''''IPO")
30 May - Board approved FY26 audited results, unmodified audit opinion, and ₹0.50 final dividend per share.
- Approval Of Audited Financial Results For Half Year & FY 2026. 30 May
-
Announcement under Regulation 30 (LODR)-Dividend Updates
30 May - Board approved FY26 audited results, recommended ₹0.50 final dividend, and reported unmodified audit opinion.
-
Board Meeting Outcome for Board Meeting Outcome For Outcome Of The Meeting Of The Board Held On May 30, 2026.
30 May - FY26 audited results approved; board recommends ₹0.50 dividend and reports unmodified opinion despite cyber incident.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
28 May - Amwill Health Care says Annual Secretarial Compliance Report is not applicable for FY2026 as an SME-listed company.
Business Overview:[1][2]
a) AHL focuses on Dermatology, Trichology, and Cosmetology.
b) It creates advanced skincare solutions using dermatological actives, natural ingredients, and specialized techniques.
c) Operates as a dermal-cosmetic developer, collaborating with contract manufacturers, distributors, and third-party developers.
d) Follows an asset-light model, outsourcing testing, manufacturing, and distribution.